Neurology Board Review: Multiple Sclerosis
Author and Disclosure Information [Show]

Michael J. Bradshaw, MD
Clinical Fellow in Neurology, Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Maria K. Houtchens, MD, MMSC
Director, Women’s Health Program, Partners Multiple Sclerosis Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

The authors have no financial relationships to disclose.

Question 1 of 5

The last 2 decades saw major advancements in treatments for patients with multiple sclerosis (MS). These treatments are known as disease-modifying therapies (DMTs). Fifteen different DMTs are now available to use in treating MS patients.

What are the main outcome measures used in the majority of clinical trials—and in clinical practice—that support efficacy claims for these agents?

Cessation of relapse activity, decrease in new or active lesions on magnetic resonance imaging (MRI), decrease in disability progression

Decrease in annualized relapse rate, decrease in disability progression, decrease in previously seen MRI lesions

Decrease in annualized relapse rate, decrease in new or active MRI lesions, decrease in disability progression

Decrease in annualized relapse rate, reversal of prior neurologic disability, decrease in new or active MRI lesions

This quiz is not accredited for CME.